CistinexineAlternative Names: Cystinhexine; REC 151884
Latest Information Update: 01 May 1996
At a glance
- Originator Recordati
- Class Expectorants
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cough
Most Recent Events
- 01 May 1996 Discontinued-Preclinical for Cough in USA (Unknown route)
- 01 May 1996 Discontinued-III for Cough in Italy (Unknown route)
- 21 Mar 1996 Investigation in Cough in Italy (Unknown route)